Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-12-21
Based on 123 first isolates · ICU · Skin / wound infection · 2024-12-22 → 2025-12-21
Intensive care unit
Per-organism detail: ICU wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 57 % (48 %–65 %)
Best two-drug combination: vancomycin + meropenem covers 98 % (94 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (14 %), Escherichia coli (14 %), Citrobacter freundii (7 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
57 %
67 %
n = 9
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
44 %
67 %
n = 9
meropenem MEM
trend · Pseudomonas aeruginosa reserve
41 %
33 %
n = 9
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
39 %
33 %
n = 9
37 %
33 %
n = 9
ceftriaxone CRO
trend · Escherichia coli
29 %
22 %
n = 9
25 %
22 %
n = 9
23 %
0 %
n = 9
11 %
11 %
n = 9
mecillinam MEC
not for this site
0 %
0 %
n = 9
trimethoprim TMP
not for this site
0 %
0 %
n = 9
nitrofurantoin NIT
not for this site
0 %
0 %
n = 9

Most likely organisms for this profile

Staphylococcus aureus
46 %
Pseudomonas aeruginosa
14 %
Escherichia coli
14 %
Enterococcus faecalis
11 %
Citrobacter freundii
7 %
Proteus mirabilis
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.